These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

754 related articles for article (PubMed ID: 17697454)

  • 1. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
    Sun SX; Liu GG; Christensen DB; Fu AZ
    Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
    Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
    Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
    Offord S; Lin J; Mirski D; Wong B
    Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions to improve antipsychotic medication adherence: review of recent literature.
    Dolder CR; Lacro JP; Leckband S; Jeste DV
    J Clin Psychopharmacol; 2003 Aug; 23(4):389-99. PubMed ID: 12920416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating the economic impact of a half-day reduction in length of hospital stay among patients with community-acquired pneumonia in the US.
    Raut M; Schein J; Mody S; Grant R; Benson C; Olson W
    Curr Med Res Opin; 2009 Sep; 25(9):2151-7. PubMed ID: 19601711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of conventional antipsychotic medications for patients with schizophrenia in a medicaid population: therapeutic and cost outcomes over 2 years.
    McCombs JS; Luo M; Johnstone BM; Shi L
    Value Health; 2000; 3(3):222-31. PubMed ID: 16464186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.
    Chen H; Kennedy WK; Dorfman JH; Fincham JE; Reeves J; Martin BC
    Curr Med Res Opin; 2007 Jun; 23(6):1351-65. PubMed ID: 17559734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial compliance in schizophrenia and the impact on patient outcomes.
    Llorca PM
    Psychiatry Res; 2008 Nov; 161(2):235-47. PubMed ID: 18849080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic burden of schizophrenia: empirical analyses from a survey in Thailand.
    Phanthunane P; Whiteford H; Vos T; Bertram M
    J Ment Health Policy Econ; 2012 Mar; 15(1):25-32. PubMed ID: 22611090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients.
    Glazer WM; Ereshefsky L
    J Clin Psychiatry; 1996 Aug; 57(8):337-45. PubMed ID: 8752015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The functionality and economic costs of outpatients with schizophrenia in Taiwan.
    Lee IH; Chen PS; Yang YK; Liao YC; Lee YD; Yeh TL; Yeh LL; Cheng SH; Chu CL
    Psychiatry Res; 2008 Apr; 158(3):306-15. PubMed ID: 18243334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS; Chung CH; Gau CS
    J Clin Psychopharmacol; 2008 Jun; 28(3):271-8. PubMed ID: 18480683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.
    Ascher-Svanum H; Furiak NM; Lawson AH; Klein TM; Smolen LJ; Conley RR; Culler SD
    J Med Econ; 2012; 15(3):531-47. PubMed ID: 22304338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of antipsychotic medication on the incidence and the costs of inpatient treatment in people with schizophrenia: results from a prospective observational study].
    Kilian R; Angermeyer MC
    Psychiatr Prax; 2004 Apr; 31(3):138-46. PubMed ID: 15042477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
    Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
    J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.